{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:29:13Z","timestamp":1792427353715,"version":"4.5.0"},"reference-count":290,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["148363"],"award-info":[{"award-number":["148363"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This article reviews the discovery of PCSK9, its structure\u2013function characteristics, and its presently known and proposed novel biological functions. The major critical function of PCSK9 deduced from human and mouse studies, as well as cellular and structural analyses, is its role in increasing the levels of circulating low-density lipoprotein (LDL)-cholesterol (LDLc), via its ability to enhance the sorting and escort of the cell surface LDL receptor (LDLR) to lysosomes. This implicates the binding of the catalytic domain of PCSK9 to the EGF-A domain of the LDLR. This also requires the presence of the C-terminal Cys\/His-rich domain, its binding to the secreted cytosolic cyclase associated protein 1, and possibly another membrane-bound \u201cprotein X\u201d. Curiously, in PCSK9-deficient mice, an alternative to the downregulation of the surface levels of the LDLR by PCSK9 is taking place in the liver of female mice in a 17\u03b2-estradiol-dependent manner by still an unknown mechanism. Recent studies have extended our understanding of the biological functions of PCSK9, namely its implication in septic shock, vascular inflammation, viral infections (Dengue; SARS-CoV-2) or immune checkpoint modulation in cancer via the regulation of the cell surface levels of the T-cell receptor and MHC-I, which govern the antitumoral activity of CD8+ T cells. Because PCSK9 inhibition may be advantageous in these processes, the availability of injectable safe PCSK9 inhibitors that reduces by 50% to 60% LDLc above the effect of statins is highly valuable. Indeed, injectable PCSK9 monoclonal antibody or small interfering RNA could be added to current immunotherapies in cancer\/metastasis.<\/jats:p>","DOI":"10.1210\/endrev\/bnab035","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T18:22:40Z","timestamp":1633803760000},"page":"558-582","source":"Crossref","is-referenced-by-count":229,"title":["The Multifaceted Biology of PCSK9"],"prefix":"10.1210","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-9342","authenticated-orcid":false,"given":"Nabil G","family":"Seidah","sequence":"first","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM, affiliated to the University of Montreal) , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-5277","authenticated-orcid":false,"given":"Annik","family":"Prat","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM, affiliated to the University of Montreal) , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"issue":"3","key":"2022053123441944300_CIT0001","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.carpath.2013.12.004","article-title":"Nikolai N. Anitschkow and the lipid hypothesis of atherosclerosis","volume":"23","author":"Buja","year":"2014","journal-title":"Cardiovasc Pathol."},{"issue":"5","key":"2022053123441944300_CIT0002","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/0002-9343(69)90020-5","article-title":"The sterol hypothesis in atherogenesis","volume":"46","author":"Frantz","year":"1969","journal-title":"Am J Med."},{"issue":"5","key":"2022053123441944300_CIT0003","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2022053123441944300_CIT0004","doi-asserted-by":"crossref","volume-title":"Triumph of the Heart: The Story of Statins.","author":"Li","DOI":"10.1093\/oso\/9780195323573.001.0001"},{"issue":"5","key":"2022053123441944300_CIT0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol."},{"issue":"6","key":"2022053123441944300_CIT0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0163-7827(01)00010-8","article-title":"Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes","volume":"40","author":"Shimano","year":"2001","journal-title":"Prog Lipid Res."},{"issue":"8","key":"2022053123441944300_CIT0007","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1194\/jlr.M100417-JLR200","article-title":"Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes","volume":"43","author":"Amemiya-Kudo","year":"2002","journal-title":"J Lipid Res."},{"issue":"4","key":"2022053123441944300_CIT0008","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"2022053123441944300_CIT0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11883-004-0113-7","article-title":"The cardioprotective effects of statins","volume":"6","author":"Davignon","year":"2004","journal-title":"Curr Atheroscler Rep."},{"issue":"6","key":"2022053123441944300_CIT0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/jm970701f","article-title":"Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption","volume":"41","author":"Rosenblum","year":"1998","journal-title":"J Med Chem."},{"issue":"12","key":"2022053123441944300_CIT0011","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11883-015-0550-5","article-title":"Role of ezetimibe in lipid-lowering and cardiovascular disease prevention","volume":"17","author":"Smith","year":"2015","journal-title":"Curr Atheroscler Rep."},{"issue":"15","key":"2022053123441944300_CIT0012","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation."},{"issue":"12","key":"2022053123441944300_CIT0013","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbagen.2012.09.014","article-title":"Site-specific protein O-glycosylation modulates proprotein processing\u2014deciphering specific functions of the large polypeptide GalNAc-transferase gene family","volume":"1820","author":"Schjoldager","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"2022053123441944300_CIT0014","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","article-title":"Global view of human protein glycosylation pathways and functions","volume":"21","author":"Schjoldager","year":"2020","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"3","key":"2022053123441944300_CIT0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nchembio.2576","article-title":"How many human proteoforms are there?","volume":"14","author":"Aebersold","year":"2018","journal-title":"Nat Chem Biol."},{"issue":"7","key":"2022053123441944300_CIT0016","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.cell.2015.05.028","article-title":"A single kinase generates the majority of the secreted phosphoproteome","volume":"161","author":"Tagliabracci","year":"2015","journal-title":"Cell."},{"key":"2022053123441944300_CIT0017","doi-asserted-by":"crossref","first-page":"e06120","DOI":"10.7554\/eLife.06120","article-title":"A secretory kinase complex regulates extracellular protein phosphorylation","volume":"4","author":"Cui","year":"2015","journal-title":"Elife."},{"issue":"7","key":"2022053123441944300_CIT0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0968-0004(89)90061-3","article-title":"Proteolytic processing and physiological regulation","volume":"14","author":"Neurath","year":"1989","journal-title":"Trends Biochem Sci."},{"issue":"11","key":"2022053123441944300_CIT0019","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.73.11.3825","article-title":"Role of proteolytic enzymes in biological regulation (a review)","volume":"73","author":"Neurath","year":"1976","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7","key":"2022053123441944300_CIT0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1139\/o83-066","article-title":"Proteases and posttranslational processing of prohormones: a review","volume":"61","author":"Lazure","year":"1983","journal-title":"Can J Biochem Cell Biol."},{"issue":"3789","key":"2022053123441944300_CIT0021","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1126\/science.157.3789.697","article-title":"Insulin biosynthesis: evidence for a precursor","volume":"157","author":"Steiner","year":"1967","journal-title":"Science."},{"key":"2022053123441944300_CIT0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61779-204-5_1","article-title":"On the discovery of precursor processing","volume":"768","author":"Steiner","year":"2011","journal-title":"Methods Mol Biol."},{"issue":"7","key":"2022053123441944300_CIT0023","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1139\/o67-133","article-title":"Isolation, purification, and characterization of gamma-lipotropic hormone from sheep pituitary glands","volume":"45","author":"Chr\u00e9tien","year":"1967","journal-title":"Can J Biochem."},{"issue":"2","key":"2022053123441944300_CIT0024","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0006-291X(76)80066-6","article-title":"Isolation of peptides with opiate activity from sheep and human pituitaries: relationship to beta-lipotropin","volume":"72","author":"Chr\u00e9tien","year":"1976","journal-title":"Biochem Biophys Res Commun."},{"key":"2022053123441944300_CIT0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fendo.2013.00148","article-title":"How the prohormone theory solved two important controversies in hormonal and neural Peptide biosynthesis","volume":"4","author":"Chr\u00e9tien","year":"2013","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7967","key":"2022053123441944300_CIT0026","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(76)91883-3","article-title":"Letter: fragment of sheep beta-lipotropin with morphine-like activity","volume":"1","author":"Seidah","year":"1976","journal-title":"Lancet."},{"issue":"1-2","key":"2022053123441944300_CIT0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0006-8993(99)01909-5","article-title":"Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides","volume":"848","author":"Seidah","year":"1999","journal-title":"Brain Res."},{"issue":"5","key":"2022053123441944300_CIT0028","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov."},{"issue":"30","key":"2022053123441944300_CIT0029","doi-asserted-by":"crossref","first-page":"21473","DOI":"10.1074\/jbc.R113.481549","article-title":"The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions","volume":"288","author":"Seidah","year":"2013","journal-title":"J Biol Chem."},{"issue":"41","key":"2022053123441944300_CIT0030","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J Biol Chem."},{"issue":"43","key":"2022053123441944300_CIT0031","doi-asserted-by":"crossref","first-page":"28261","DOI":"10.1074\/jbc.273.43.28261","article-title":"Isolation of cholesterol-requiring mutant Chinese hamster ovary cells with defects in cleavage of sterol regulatory element-binding proteins at site 1","volume":"273","author":"Rawson","year":"1998","journal-title":"J Biol Chem."},{"issue":"22","key":"2022053123441944300_CIT0032","doi-asserted-by":"crossref","first-page":"12701","DOI":"10.1073\/pnas.221447598","article-title":"The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1\/S1P","volume":"98","author":"Lenz","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"16","key":"2022053123441944300_CIT0033","doi-asserted-by":"crossref","first-page":"8640","DOI":"10.1128\/JVI.77.16.8640-8649.2003","article-title":"Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1","volume":"77","author":"Vincent","year":"2003","journal-title":"J Virol."},{"issue":"4","key":"2022053123441944300_CIT0034","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1073\/pnas.96.4.1321","article-title":"Mammalian subtilisin\/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization","volume":"96","author":"Seidah","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"2022053123441944300_CIT0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1097-2765(00)80150-1","article-title":"Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells","volume":"2","author":"Sakai","year":"1998","journal-title":"Mol Cell."},{"issue":"6","key":"2022053123441944300_CIT0036","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1097-2765(00)00133-7","article-title":"ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs","volume":"6","author":"Ye","year":"2000","journal-title":"Mol Cell."},{"key":"2022053123441944300_CIT0037","first-page":"1","article-title":"Proprotein convertases SKI-1\/S1P and PCSK9","volume-title":"Handbook of the Biologically Active Peptides","author":"Seidah","year":"2012"},{"issue":"32","key":"2022053123441944300_CIT0038","doi-asserted-by":"crossref","first-page":"22795","DOI":"10.1074\/jbc.274.32.22795","article-title":"Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins","volume":"274","author":"Espenshade","year":"1999","journal-title":"J Biol Chem."},{"issue":"17","key":"2022053123441944300_CIT0039","doi-asserted-by":"crossref","first-page":"17338","DOI":"10.1074\/jbc.M313764200","article-title":"Development of protein-based inhibitors of the proprotein of convertase SKI-1\/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein","volume":"279","author":"Pullikotil","year":"2004","journal-title":"J Biol Chem."},{"issue":"33","key":"2022053123441944300_CIT0040","doi-asserted-by":"crossref","first-page":"23471","DOI":"10.1074\/jbc.M513675200","article-title":"The proprotein convertase SKI-1\/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors","volume":"281","author":"Pasquato","year":"2006","journal-title":"J Biol Chem."},{"key":"2022053123441944300_CIT0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/bse0380079","article-title":"Precursor convertases in the secretory pathway, cytosol and extracellular milieu","volume":"38","author":"Seidah","year":"2002","journal-title":"Essays Biochem."},{"issue":"7","key":"2022053123441944300_CIT0042","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00109-007-0172-7","article-title":"The proprotein convertases are potential targets in the treatment of dyslipidemia","volume":"85","author":"Seidah","year":"2007","journal-title":"J Mol Med (Berl)."},{"key":"2022053123441944300_CIT0043","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-319-75474-1_3","article-title":"Cleavage of the glycoprotein of arenaviruses","author":"Pasquato","year":"2018","journal-title":"Activat Viruses Host Proteases"},{"issue":"11 Pt B","key":"2022053123441944300_CIT0044","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.bbamcr.2017.06.023","article-title":"Site-1 protease and lysosomal homeostasis","volume":"1864","author":"Velho","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Res."},{"issue":"2","key":"2022053123441944300_CIT0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.devcel.2011.11.022","article-title":"SKI-1 and Furin generate multiple RGMa fragments that regulate axonal growth","volume":"22","author":"Tassew","year":"2012","journal-title":"Dev Cell."},{"issue":"4","key":"2022053123441944300_CIT0046","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jb\/mvw080","article-title":"Site-1 protease is required for the generation of soluble (pro)renin receptor","volume":"161","author":"Nakagawa","year":"2017","journal-title":"J Biochem."},{"issue":"7","key":"2022053123441944300_CIT0047","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/v13071229","article-title":"How do enveloped viruses exploit the secretory proprotein convertases to regulate infectivity and spread?","volume":"13","author":"Seidah","year":"2021","journal-title":"Viruses"},{"issue":"14","key":"2022053123441944300_CIT0048","doi-asserted-by":"crossref","first-page":"e121596","DOI":"10.1172\/jci.insight.121596","article-title":"Site-1 protease deficiency causes human skeletal dysplasia due to defective inter-organelle protein trafficking","volume":"3","author":"Kondo","year":"2018","journal-title":"JCI Insight"},{"issue":"30","key":"2022053123441944300_CIT0049","doi-asserted-by":"crossref","first-page":"10271","DOI":"10.1074\/jbc.REV120.012669","article-title":"Transcription factors activated through RIP (regulated intramembrane proteolysis) and RAT (regulated alternative translocation)","volume":"295","author":"Ye","year":"2020","journal-title":"J Biol Chem."},{"issue":"6038","key":"2022053123441944300_CIT0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.1205677","article-title":"A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism","volume":"333","author":"Marschner","year":"2011","journal-title":"Science."},{"issue":"3","key":"2022053123441944300_CIT0051","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2022053123441944300_CIT0052","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet."},{"issue":"5","key":"2022053123441944300_CIT0053","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1086\/302370","article-title":"A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32","volume":"64","author":"Varret","year":"1999","journal-title":"Am J Hum Genet."},{"issue":"4","key":"2022053123441944300_CIT0054","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.ATV.20.4.1089","article-title":"Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred","volume":"20","author":"Hunt","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"2022053123441944300_CIT0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.abb.2003.09.011","article-title":"Functional characterization of Narc 1, a novel proteinase related to proteinase K","volume":"420","author":"Naureckiene","year":"2003","journal-title":"Arch Biochem Biophys."},{"issue":"47","key":"2022053123441944300_CIT0056","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem."},{"issue":"40","key":"2022053123441944300_CIT0057","doi-asserted-by":"crossref","first-page":"33745","DOI":"10.1074\/jbc.M112.399725","article-title":"Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation","volume":"287","author":"Benjannet","year":"2012","journal-title":"J Biol Chem."},{"issue":"8","key":"2022053123441944300_CIT0058","doi-asserted-by":"crossref","first-page":"e72113","DOI":"10.1371\/journal.pone.0072113","article-title":"PCSK9 prosegment chimera as novel inhibitors of LDLR degradation","volume":"8","author":"Saavedra","year":"2013","journal-title":"PLoS One."},{"issue":"5","key":"2022053123441944300_CIT0059","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol."},{"issue":"5","key":"2022053123441944300_CIT0060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure."},{"issue":"4","key":"2022053123441944300_CIT0061","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"2022053123441944300_CIT0062","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2022053123441944300_CIT0063","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"48","key":"2022053123441944300_CIT0064","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem."},{"issue":"11","key":"2022053123441944300_CIT0065","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J Lipid Res."},{"issue":"21","key":"2022053123441944300_CIT0066","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1073\/pnas.1534923100","article-title":"Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes","volume":"100","author":"Horton","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"2022053123441944300_CIT0067","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"5","key":"2022053123441944300_CIT0068","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmet.2005.04.006","article-title":"Dual regulation of the LDL receptor\u2013some clarity and new questions","volume":"1","author":"Attie","year":"2005","journal-title":"Cell Metab."},{"issue":"4","key":"2022053123441944300_CIT0069","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum Genet."},{"issue":"2","key":"2022053123441944300_CIT0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet."},{"issue":"12","key":"2022053123441944300_CIT0071","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med."},{"issue":"24","key":"2022053123441944300_CIT0072","doi-asserted-by":"crossref","first-page":"13607","DOI":"10.1073\/pnas.201524598","article-title":"Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene","volume":"98","author":"Yang","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"15","key":"2022053123441944300_CIT0073","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2022053123441944300_CIT0074","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet."},{"issue":"2","key":"2022053123441944300_CIT0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis."},{"issue":"29","key":"2022053123441944300_CIT0076","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J Biol Chem."},{"issue":"4","key":"2022053123441944300_CIT0077","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem."},{"issue":"10","key":"2022053123441944300_CIT0078","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin Chem."},{"issue":"2","key":"2022053123441944300_CIT0079","doi-asserted-by":"crossref","first-page":"e128650","DOI":"10.1172\/JCI128650","article-title":"The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury","volume":"131","author":"Lebeau","year":"2021","journal-title":"J Clin Invest."},{"issue":"12","key":"2022053123441944300_CIT0080","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Lo Surdo","year":"2011","journal-title":"EMBO Rep."},{"issue":"6","key":"2022053123441944300_CIT0081","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2022053123441944300_CIT0082","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2011.02.023","article-title":"Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor","volume":"406","author":"Holla","year":"2011","journal-title":"Biochem Biophys Res Commun."},{"issue":"52","key":"2022053123441944300_CIT0083","doi-asserted-by":"crossref","first-page":"40965","DOI":"10.1074\/jbc.M110.154815","article-title":"Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events","volume":"285","author":"Benjannet","year":"2010","journal-title":"J Biol Chem."},{"issue":"5","key":"2022053123441944300_CIT0084","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jmb.2019.01.015","article-title":"The elusive inhibitory function of the acidic N-terminal segment of the prodomain of PCSK9: the plot thickens","volume":"431","author":"Seidah","year":"2019","journal-title":"J Mol Biol."},{"issue":"5","key":"2022053123441944300_CIT0085","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"10","key":"2022053123441944300_CIT0086","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/ATVBAHA.119.313247","article-title":"Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (family with sequence similarity 20, Member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor)","volume":"39","author":"Ben Djoudi Ouadda","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"2022053123441944300_CIT0087","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic."},{"issue":"7","key":"2022053123441944300_CIT0088","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J Lipid Res."},{"key":"2022053123441944300_CIT0089","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2121-8-9","article-title":"Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly","volume":"8","author":"Holla","year":"2007","journal-title":"BMC Cell Biol."},{"issue":"11","key":"2022053123441944300_CIT0090","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest."},{"issue":"25","key":"2022053123441944300_CIT0091","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem."},{"issue":"42","key":"2022053123441944300_CIT0092","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J Biol Chem."},{"issue":"5","key":"2022053123441944300_CIT0093","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1074\/jbc.M116.769430","article-title":"The proprotein convertase subtilisin\/kexin type 9-resistant R410S low density lipoprotein receptor mutation: a novel mechanism causing familial hypercholesterolemia","volume":"292","author":"Susan-Resiga","year":"2017","journal-title":"J Biol Chem."},{"issue":"3","key":"2022053123441944300_CIT0094","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/febs.15036","article-title":"Functional analysis of natural PCSK9 mutants in modern and archaic humans","volume":"287","author":"Mikaeeli","year":"2020","journal-title":"FEBS J."},{"issue":"1","key":"2022053123441944300_CIT0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol Rev."},{"issue":"6","key":"2022053123441944300_CIT0096","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res."},{"issue":"9","key":"2022053123441944300_CIT0097","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1161\/ATVBAHA.120.314194","article-title":"Circulating rather than intestinal PCSK9 (proprotein convertase subtilisin kexin type 9) regulates postprandial lipemia in mice","volume":"40","author":"Gar\u00e7on","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"8","key":"2022053123441944300_CIT0098","doi-asserted-by":"crossref","first-page":"158968","DOI":"10.1016\/j.bbalip.2021.158968","article-title":"Substantial PCSK9 inactivation in \u03b2-cells does not modify glucose homeostasis or insulin secretion in mice","volume":"1866","author":"Peyot","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids."},{"key":"2022053123441944300_CIT0099","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2021.03.044","article-title":"Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function","volume":"326","author":"Ramin-Mangata","year":"2021","journal-title":"Atherosclerosis."},{"issue":"10","key":"2022053123441944300_CIT0100","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin Chem."},{"issue":"2","key":"2022053123441944300_CIT0101","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbrc.2007.07.029","article-title":"Plasma PCSK9 levels correlate with cholesterol in men but not in women","volume":"361","author":"Mayne","year":"2007","journal-title":"Biochem Biophys Res Commun."},{"issue":"6","key":"2022053123441944300_CIT0102","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin Chem."},{"issue":"7","key":"2022053123441944300_CIT0103","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022053123441944300_CIT0104","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res."},{"issue":"1","key":"2022053123441944300_CIT0105","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","article-title":"Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial","volume":"58","author":"Awan","year":"2012","journal-title":"Clin Chem."},{"issue":"5","key":"2022053123441944300_CIT0106","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum Mutat."},{"issue":"9","key":"2022053123441944300_CIT0107","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","article-title":"Effect of mutations in the PCSK9 gene on the cell surface LDL receptors","volume":"15","author":"Cameron","year":"2006","journal-title":"Hum Mol Genet."},{"issue":"6","key":"2022053123441944300_CIT0108","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J Biol Chem."},{"issue":"2","key":"2022053123441944300_CIT0109","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"Bottomley","year":"2009","journal-title":"J Biol Chem."},{"issue":"16","key":"2022053123441944300_CIT0110","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J Biol Chem."},{"issue":"37","key":"2022053123441944300_CIT0111","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.0703402104","article-title":"The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain","volume":"104","author":"Hampton","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2022053123441944300_CIT0112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clim.2009.07.013","article-title":"The role of resistin as a regulator of inflammation: Implications for various human pathologies","volume":"133","author":"Filkov\u00e1","year":"2009","journal-title":"Clin Immunol."},{"issue":"2","key":"2022053123441944300_CIT0113","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","article-title":"Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants","volume":"28","author":"Dron","year":"2017","journal-title":"Curr Opin Lipidol."},{"issue":"1","key":"2022053123441944300_CIT0114","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41598-018-20281-9","article-title":"New sequencing technologies help revealing unexpected mutations in autosomal dominant hypercholesterolemia","volume":"8","author":"Elbitar","year":"2018","journal-title":"Sci Rep."},{"issue":"3","key":"2022053123441944300_CIT0115","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet."},{"issue":"12","key":"2022053123441944300_CIT0116","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"4","key":"2022053123441944300_CIT0117","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat."},{"issue":"10","key":"2022053123441944300_CIT0118","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.cjca.2018.07.479","article-title":"Whole-gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia","volume":"34","author":"Iacocca","year":"2018","journal-title":"Can J Cardiol."},{"issue":"10","key":"2022053123441944300_CIT0119","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.celrep.2015.11.006","article-title":"GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation","volume":"13","author":"Poirier","year":"2015","journal-title":"Cell Rep."},{"issue":"7","key":"2022053123441944300_CIT0120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/jcp.24923","article-title":"Role of the unfolded protein response, GRP78 and GRP94 in organ homeostasis","volume":"230","author":"Zhu","year":"2015","journal-title":"J Cell Physiol."},{"issue":"8","key":"2022053123441944300_CIT0121","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/jcb.25481","article-title":"GRP78 interacting partner Bag5 responds to ER stress and protects cardiomyocytes from ER stress-induced apoptosis","volume":"117","author":"Gupta","year":"2016","journal-title":"J Cell Biochem."},{"issue":"1","key":"2022053123441944300_CIT0122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neo.2016.11.007","article-title":"GALNT6 stabilizes GRP78 protein by O-glycosylation and enhances its activity to suppress apoptosis under stress condition","volume":"19","author":"Lin","year":"2017","journal-title":"Neoplasia."},{"issue":"2","key":"2022053123441944300_CIT0123","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis."},{"key":"2022053123441944300_CIT0124","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50(Suppl)","author":"Horton","year":"2009","journal-title":"J Lipid Res."},{"issue":"35","key":"2022053123441944300_CIT0125","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.0806312105","article-title":"Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"2022053123441944300_CIT0126","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1194\/jlr.M018093","article-title":"Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors","volume":"52","author":"Holla","year":"2011","journal-title":"J Lipid Res."},{"issue":"17","key":"2022053123441944300_CIT0127","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J Biol Chem."},{"issue":"1","key":"2022053123441944300_CIT0128","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2008.10.027","article-title":"Degradation of LDLR protein mediated by \u2018gain of function\u2019 PCSK9 mutants in normal and ARH cells","volume":"203","author":"Fasano","year":"2009","journal-title":"Atherosclerosis."},{"issue":"1","key":"2022053123441944300_CIT0129","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2010.05.003","article-title":"Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain","volume":"101","author":"Str\u00f8m","year":"2010","journal-title":"Mol Genet Metab."},{"issue":"1","key":"2022053123441944300_CIT0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ymgme.2011.10.008","article-title":"Characterization of a naturally occurring degradation product of the LDL receptor","volume":"105","author":"Tveten","year":"2012","journal-title":"Mol Genet Metab."},{"issue":"5","key":"2022053123441944300_CIT0131","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One."},{"issue":"4","key":"2022053123441944300_CIT0132","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jmb.2013.11.011","article-title":"An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo","volume":"426","author":"Schiele","year":"2014","journal-title":"J Mol Biol."},{"issue":"32","key":"2022053123441944300_CIT0133","doi-asserted-by":"crossref","first-page":"16659","DOI":"10.1074\/jbc.M116.717736","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation","volume":"291","author":"Weider","year":"2016","journal-title":"J Biol Chem."},{"issue":"12","key":"2022053123441944300_CIT0134","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1515\/hsz-2018-0194","article-title":"A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice","volume":"399","author":"Essalmani","year":"2018","journal-title":"Biol Chem."},{"issue":"30","key":"2022053123441944300_CIT0135","doi-asserted-by":"crossref","first-page":"18609","DOI":"10.1074\/jbc.M115.647180","article-title":"Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9 convertase-mediated low density lipoprotein receptor degradation but interact with each other","volume":"290","author":"Butkinaree","year":"2015","journal-title":"J Biol Chem."},{"issue":"6","key":"2022053123441944300_CIT0136","doi-asserted-by":"crossref","first-page":"e0157230","DOI":"10.1371\/journal.pone.0157230","article-title":"Trafficking dynamics of PCSK9-induced LDLR degradation: focus on human PCSK9 mutations and C-terminal domain","volume":"11","author":"Poirier","year":"2016","journal-title":"PLoS One."},{"issue":"1","key":"2022053123441944300_CIT0137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1194\/jlr.M087189","article-title":"Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake","volume":"60","author":"Galvan","year":"2019","journal-title":"J Lipid Res."},{"issue":"2","key":"2022053123441944300_CIT0138","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/eurheartj\/ehz566","article-title":"Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin\/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin\/kexin type-9","volume":"41","author":"Jang","year":"2020","journal-title":"Eur Heart J."},{"issue":"12","key":"2022053123441944300_CIT0139","doi-asserted-by":"crossref","first-page":"jcs213686","DOI":"10.1242\/jcs.213686","article-title":"Unconventional protein secretion - new insights into the pathogenesis and therapeutic targets of human diseases","volume":"131","author":"Kim","year":"2018","journal-title":"J Cell Sci."},{"issue":"46","key":"2022053123441944300_CIT0140","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels","volume":"283","author":"Mayer","year":"2008","journal-title":"J Biol Chem."},{"issue":"52","key":"2022053123441944300_CIT0141","doi-asserted-by":"crossref","first-page":"43492","DOI":"10.1074\/jbc.M112.394023","article-title":"The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway","volume":"287","author":"Saavedra","year":"2012","journal-title":"J Biol Chem."},{"issue":"10","key":"2022053123441944300_CIT0142","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nsmb.3471","article-title":"Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol","volume":"24","author":"Seidah","year":"2017","journal-title":"Nat Struct Mol Biol."},{"issue":"2","key":"2022053123441944300_CIT0143","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology."},{"issue":"7","key":"2022053123441944300_CIT0144","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1194\/jlr.M014118","article-title":"PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke","volume":"52","author":"Rousselet","year":"2011","journal-title":"J Lipid Res."},{"issue":"3","key":"2022053123441944300_CIT0145","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","article-title":"Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system","volume":"98","author":"Poirier","year":"2006","journal-title":"J Neurochem."},{"issue":"10","key":"2022053123441944300_CIT0146","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/liv.14993","article-title":"Proprotein convertase subtilisin\/kexin type 9 regulates the production of acute-phase reactants from the liver","volume":"41","author":"Jacome Sanz","year":"2021","journal-title":"Liver Int."},{"issue":"9","key":"2022053123441944300_CIT0147","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1194\/jlr.M006635","article-title":"PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain","volume":"51","author":"Liu","year":"2010","journal-title":"J Lipid Res."},{"issue":"9","key":"2022053123441944300_CIT0148","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1194\/jlr.M038331","article-title":"Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression","volume":"54","author":"Parker","year":"2013","journal-title":"J Lipid Res."},{"issue":"11","key":"2022053123441944300_CIT0149","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1194\/jlr.M061952","article-title":"PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice","volume":"56","author":"Roubtsova","year":"2015","journal-title":"J Lipid Res."},{"issue":"10","key":"2022053123441944300_CIT0150","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J Biol Chem."},{"issue":"12","key":"2022053123441944300_CIT0151","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"7","key":"2022053123441944300_CIT0152","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/ATVBAHA.110.204040","article-title":"Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control","volume":"30","author":"Herbert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"11","key":"2022053123441944300_CIT0153","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/CIRCRESAHA.114.302937","article-title":"Induction of atherosclerosis in mice and hamsters without germline genetic engineering","volume":"114","author":"Bj\u00f8rklund","year":"2014","journal-title":"Circ Res."},{"issue":"7","key":"2022053123441944300_CIT0154","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation."},{"key":"2022053123441944300_CIT0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis."},{"issue":"5","key":"2022053123441944300_CIT0156","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jacc.2006.06.001","article-title":"Oxidized or native low-density lipoprotein cholesterol: which is more important in atherogenesis?","volume":"48","author":"Mehta","year":"2006","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"2022053123441944300_CIT0157","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc Res."},{"issue":"32","key":"2022053123441944300_CIT0158","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur Heart J."},{"issue":"8","key":"2022053123441944300_CIT0159","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","article-title":"PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc Res."},{"issue":"4","key":"2022053123441944300_CIT0160","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem Biophys Res Commun."},{"issue":"7727","key":"2022053123441944300_CIT0161","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41586-018-0590-4","article-title":"Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris","volume":"562","author":"The Tabula Muris Consortium","year":"2018","journal-title":"Nature"},{"issue":"1","key":"2022053123441944300_CIT0162","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"issue":"3","key":"2022053123441944300_CIT0163","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cvr\/cvz003","article-title":"Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies","volume":"115","author":"Seidah","year":"2019","journal-title":"Cardiovasc Res."},{"key":"2022053123441944300_CIT0164","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2021.06.903","article-title":"The emerging landscape of peptide-based inhibitors of PCSK9","volume":"330","author":"Tombling","year":"2021","journal-title":"Atherosclerosis."},{"issue":"1","key":"2022053123441944300_CIT0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med."},{"issue":"7","key":"2022053123441944300_CIT0166","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-020-00847-7","article-title":"New pharmacological approaches to target PCSK9","volume":"22","author":"Catapano","year":"2020","journal-title":"Curr Atheroscler Rep."},{"issue":"5","key":"2022053123441944300_CIT0167","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2174\/0929867327666200505091738","article-title":"Three musketeers for lowering cholesterol: statins, ezetimibe and evolocumab","volume":"28","author":"Xu","year":"2021","journal-title":"Curr Med Chem."},{"issue":"9","key":"2022053123441944300_CIT0168","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jacc.2021.01.008","article-title":"Inclisiran: a game changer in a changing game?","volume":"77","author":"Nambi","year":"2021","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"2022053123441944300_CIT0169","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21873\/invivo.12232","article-title":"PCSK9 antibody-based treatment strategies for patients with statin intolerance","volume":"35","author":"Voutyritsa","year":"2021","journal-title":"In Vivo."},{"key":"2022053123441944300_CIT0170","doi-asserted-by":"crossref","DOI":"10.1007\/s40256-021-00477-7","article-title":"A critical review of the efficacy and safety of inclisiran","author":"Hardy","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2022053123441944300_CIT0171","doi-asserted-by":"crossref","first-page":"595819","DOI":"10.3389\/fphys.2020.595819","article-title":"PCSK9 inhibition: insights from clinical trials and future prospects","volume":"11","author":"Katzmann","year":"2020","journal-title":"Front Physiol."},{"issue":"5","key":"2022053123441944300_CIT0172","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11883-021-00918-3","article-title":"Lipid lowering drugs: present status and future developments","volume":"23","author":"Ruscica","year":"2021","journal-title":"Curr Atheroscler Rep."},{"issue":"3","key":"2022053123441944300_CIT0173","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjcvp\/pvaa024","article-title":"Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis","volume":"7","author":"Guedeney","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"5","key":"2022053123441944300_CIT0174","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1358\/dot.2021.57.5.3277083","article-title":"Inclisiran in dyslipidemia","volume":"57","author":"Kosmas","year":"2021","journal-title":"Drugs Today (Barc)."},{"key":"2022053123441944300_CIT0175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-med-022613-090402","article-title":"Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9","volume":"65","author":"Stein","year":"2014","journal-title":"Annu Rev Med."},{"issue":"24","key":"2022053123441944300_CIT0176","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"23","key":"2022053123441944300_CIT0177","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"2022053123441944300_CIT0178","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol."},{"issue":"4","key":"2022053123441944300_CIT0179","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/1570161118666200807114559","article-title":"PCSK9 Inhibitors and ezetimibe monotherapy in patients not receiving statins: a meta-analysis of randomized trials","volume":"19","author":"Benhuri","year":"2021","journal-title":"Curr Vasc Pharmacol."},{"issue":"6","key":"2022053123441944300_CIT0180","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/bcp.13066","article-title":"Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia","volume":"82","author":"Gouni-Berthold","year":"2016","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"2022053123441944300_CIT0181","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.766","article-title":"PCSK9 inhibition with monoclonal antibodies-modern management of hypercholesterolemia","volume":"57","author":"Ito","year":"2017","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"2022053123441944300_CIT0182","doi-asserted-by":"crossref","first-page":"e003323","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"2022053123441944300_CIT0183","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1194\/jlr.P088583","article-title":"The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption","volume":"60","author":"Silbernagel","year":"2019","journal-title":"J Lipid Res."},{"issue":"1","key":"2022053123441944300_CIT0184","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10557-019-06852-6","article-title":"Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia","volume":"33","author":"Ginsberg","year":"2019","journal-title":"Cardiovasc Drugs Ther."},{"issue":"1","key":"2022053123441944300_CIT0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jacl.2016.12.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Kastelein","year":"2017","journal-title":"J Clin Lipidol."},{"issue":"3","key":"2022053123441944300_CIT0186","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"18","key":"2022053123441944300_CIT0187","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2022053123441944300_CIT0188","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"22","key":"2022053123441944300_CIT0189","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"2022053123441944300_CIT0190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamacardio.2020.0764","article-title":"Effect of evolocumab on type and size of subsequent myocardial infarction: a prespecified analysis of the FOURIER randomized clinical trial","volume":"5","author":"Wiviott","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"2","key":"2022053123441944300_CIT0191","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","article-title":"Efficacy and Safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial","volume":"6","author":"Deedwania","year":"2021","journal-title":"JAMA Cardiol."},{"issue":"4","key":"2022053123441944300_CIT0192","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA."},{"issue":"3","key":"2022053123441944300_CIT0193","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MOL.0000000000000499","article-title":"The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?","volume":"29","author":"Boffa","year":"2018","journal-title":"Curr Opin Lipidol."},{"issue":"18","key":"2022053123441944300_CIT0194","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J Biol Chem."},{"issue":"7","key":"2022053123441944300_CIT0195","doi-asserted-by":"crossref","first-page":"e0180869","DOI":"10.1371\/journal.pone.0180869","article-title":"Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by PCSK9","volume":"12","author":"Romagnuolo","year":"2017","journal-title":"PLoS One."},{"key":"2022053123441944300_CIT0196","doi-asserted-by":"crossref","first-page":"cvab247","DOI":"10.1093\/cvr\/cvab247","article-title":"The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors","author":"Blanchard","year":"2021","journal-title":"Cardiovasc Res."},{"issue":"6","key":"2022053123441944300_CIT0197","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci."},{"issue":"9","key":"2022053123441944300_CIT0198","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"21","key":"2022053123441944300_CIT0199","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"2022053123441944300_CIT0200","doi-asserted-by":"crossref","first-page":"101177","DOI":"10.1016\/j.jbc.2021.101177","article-title":"Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin","volume":"297","author":"Susan-Resiga","year":"2021","journal-title":"J Biol Chem."},{"key":"2022053123441944300_CIT0201","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","article-title":"Trends in lipid-modifying agent use in 83 countries","volume":"328","author":"Blais","year":"2021","journal-title":"Atherosclerosis."},{"issue":"9","key":"2022053123441944300_CIT0202","doi-asserted-by":"crossref","first-page":"e019331","DOI":"10.1161\/JAHA.120.019331","article-title":"Adoption of PCSK9 inhibitors among patients with atherosclerotic disease","volume":"10","author":"Dayoub","year":"2021","journal-title":"J Am Heart Assoc."},{"issue":"11","key":"2022053123441944300_CIT0203","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7326\/M19-0365","article-title":"2018 Cholesterol clinical practice guidelines: synopsis of the 2018 American Heart Association\/American College of Cardiology\/Multisociety cholesterol guideline","volume":"170","author":"Grundy","year":"2019","journal-title":"Ann Intern Med."},{"issue":"43","key":"2022053123441944300_CIT0204","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine."},{"issue":"1","key":"2022053123441944300_CIT0205","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","article-title":"A therapeutic peptide vaccine against PCSK9","volume":"7","author":"Pan","year":"2017","journal-title":"Sci Rep."},{"issue":"2","key":"2022053123441944300_CIT0206","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40119-020-00191-6","article-title":"Vaccines targeting PSCK9 for the treatment of hyperlipidemia","volume":"9","author":"Toth","year":"2020","journal-title":"Cardiol Ther."},{"issue":"1","key":"2022053123441944300_CIT0207","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41467-020-20251-8","article-title":"Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity","volume":"12","author":"Fougeroux","year":"2021","journal-title":"Nat Commun."},{"issue":"6096","key":"2022053123441944300_CIT0208","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science."},{"issue":"7","key":"2022053123441944300_CIT0209","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.3390\/ijms22073327","article-title":"Novel CRISPR-cas systems: an updated review of the current achievements, applications, and future research perspectives","volume":"22","author":"Nidhi","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"1","key":"2022053123441944300_CIT0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp2030694","article-title":"Human molecular genetics and genomics\u2014important advances and exciting possibilities","volume":"384","author":"Collins","year":"2021","journal-title":"N Engl J Med."},{"issue":"1","key":"2022053123441944300_CIT0211","doi-asserted-by":"crossref","first-page":"100789","DOI":"10.1016\/j.isci.2019.100789","article-title":"Sharpening the molecular scissors: advances in gene-editing technology","volume":"23","author":"Broeders","year":"2020","journal-title":"Iscience."},{"issue":"5","key":"2022053123441944300_CIT0212","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ Res."},{"issue":"10","key":"2022053123441944300_CIT0213","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat Med."},{"issue":"21","key":"2022053123441944300_CIT0214","doi-asserted-by":"crossref","first-page":"eaba2983","DOI":"10.1126\/sciadv.aba2983","article-title":"CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation","volume":"6","author":"Sun","year":"2020","journal-title":"Sci Adv."},{"issue":"1","key":"2022053123441944300_CIT0215","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat Commun."},{"issue":"7859","key":"2022053123441944300_CIT0216","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature."},{"issue":"8","key":"2022053123441944300_CIT0217","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"issue":"16","key":"2022053123441944300_CIT0218","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJMra043632","article-title":"Management of sepsis","volume":"355","author":"Russell","year":"2006","journal-title":"N Engl J Med."},{"issue":"258","key":"2022053123441944300_CIT0219","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med."},{"issue":"2","key":"2022053123441944300_CIT0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J Innate Immun."},{"issue":"5","key":"2022053123441944300_CIT0221","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MCC.0000000000000351","article-title":"Role of lipoproteins and proprotein convertase subtilisin\/kexin type 9 in endotoxin clearance in sepsis","volume":"22","author":"Walley","year":"2016","journal-title":"Curr Opin Crit Care."},{"issue":"6","key":"2022053123441944300_CIT0222","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock."},{"issue":"1","key":"2022053123441944300_CIT0223","doi-asserted-by":"crossref","first-page":"10496","DOI":"10.1038\/s41598-018-28777-0","article-title":"Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor","volume":"8","author":"Grin","year":"2018","journal-title":"Sci Rep."},{"key":"2022053123441944300_CIT0224","doi-asserted-by":"crossref","first-page":"2687692","DOI":"10.1155\/2020\/2687692","article-title":"PCSK9: a potential therapeutic target for sepsis","volume":"2020","author":"Yuan","year":"2020","journal-title":"J Immunol Res."},{"issue":"1","key":"2022053123441944300_CIT0225","doi-asserted-by":"crossref","first-page":"10588","DOI":"10.1038\/s41598-019-46745-0","article-title":"Reduced Proprotein convertase subtilisin\/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients","volume":"9","author":"Leung","year":"2019","journal-title":"Sci Rep."},{"issue":"9","key":"2022053123441944300_CIT0226","doi-asserted-by":"crossref","first-page":"e1911130","DOI":"10.1001\/jamanetworkopen.2019.11130","article-title":"A genetic approach to the association between PCSK9 and sepsis","volume":"2","author":"Feng","year":"2019","journal-title":"JAMA Netw Open."},{"key":"2022053123441944300_CIT0227","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ebiom.2018.11.032","article-title":"Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors","volume":"38","author":"Genga","year":"2018","journal-title":"Ebiomedicine."},{"issue":"1","key":"2022053123441944300_CIT0228","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/CCM.0000000000004064","article-title":"Very low density lipoprotein receptor sequesters lipopolysaccharide into adipose tissue during sepsis","volume":"48","author":"Shimada","year":"2020","journal-title":"Crit Care Med."},{"issue":"6","key":"2022053123441944300_CIT0229","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1189\/jlb.5MR0315-127R","article-title":"The future of murine sepsis and trauma research models","volume":"98","author":"Efron","year":"2015","journal-title":"J Leukoc Biol."},{"issue":"6","key":"2022053123441944300_CIT0230","doi-asserted-by":"crossref","first-page":"e2001930","DOI":"10.1371\/journal.pbio.2001930","article-title":"MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression","volume":"15","author":"Shaler","year":"2017","journal-title":"PLoS Biol."},{"issue":"5","key":"2022053123441944300_CIT0231","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3390\/ijms22052403","article-title":"Humanized mice as a tool to study sepsis\u2014more than meets the eye","volume":"22","author":"Laudanski","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"10","key":"2022053123441944300_CIT0232","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/CCM.0000000000004487","article-title":"Proprotein convertase subtilisin\/kexin type 9 loss-of-function is detrimental to the juvenile host with septic shock","volume":"48","author":"Atreya","year":"2020","journal-title":"Crit Care Med."},{"issue":"2","key":"2022053123441944300_CIT0233","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/joim.13150","article-title":"PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study","volume":"289","author":"Vecchi\u00e9","year":"2021","journal-title":"J Intern Med."},{"issue":"1","key":"2022053123441944300_CIT0234","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10238-020-00658-9","article-title":"Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department","volume":"21","author":"Innocenti","year":"2021","journal-title":"Clin Exp Med."},{"issue":"5","key":"2022053123441944300_CIT0235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/joim.12946","article-title":"Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality","volume":"286","author":"Rannikko","year":"2019","journal-title":"J Intern Med."},{"issue":"2","key":"2022053123441944300_CIT0236","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOL.0000000000000577","article-title":"Molecular regulation of plasma lipid levels during systemic inflammation and sepsis","volume":"30","author":"Trinder","year":"2019","journal-title":"Curr Opin Lipidol."},{"issue":"3","key":"2022053123441944300_CIT0237","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2006.09.024","article-title":"The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus","volume":"46","author":"Molina","year":"2007","journal-title":"J Hepatol."},{"issue":"5","key":"2022053123441944300_CIT0238","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/v5051292","article-title":"Hepatitis C virus, cholesterol and lipoproteins\u2013impact for the viral life cycle and pathogenesis of liver disease","volume":"5","author":"Felmlee","year":"2013","journal-title":"Viruses."},{"issue":"1","key":"2022053123441944300_CIT0239","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13287-019-1342-6","article-title":"Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR\/Cas-mediated genetic correction, and productive hepatitis C virus infection","volume":"10","author":"Caron","year":"2019","journal-title":"Stem Cell Res Ther."},{"issue":"3","key":"2022053123441944300_CIT0240","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D\u2019Ambrosio","year":"2019","journal-title":"J Hepatol."},{"key":"2022053123441944300_CIT0241","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2017.08.020","article-title":"Treatment-induced viral cure of hepatitis C virus-infected patients involves a dynamic interplay among three important molecular players in lipid homeostasis: circulating microRNA (miR)-24, miR-223, and proprotein convertase subtilisin\/kexin type 9","volume":"23","author":"Hyrina","year":"2017","journal-title":"Ebiomedicine."},{"issue":"4","key":"2022053123441944300_CIT0242","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2014.11.016","article-title":"PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism","volume":"62","author":"Bridge","year":"2015","journal-title":"J Hepatol."},{"issue":"8","key":"2022053123441944300_CIT0243","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3390\/jcm10081621","article-title":"Rapid decline of serum proprotein convertase subtilisin\/kexin 9 (PCSK9) in non-cirrhotic patients with chronic hepatitis C infection receiving direct-acting antiviral therapy","volume":"10","author":"Grimm","year":"2021","journal-title":"J Clin Med."},{"issue":"1","key":"2022053123441944300_CIT0244","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression","volume":"50","author":"Labont\u00e9","year":"2009","journal-title":"Hepatology."},{"issue":"3","key":"2022053123441944300_CIT0245","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOL.0000000000000295","article-title":"New developments in proprotein convertase subtilisin-kexin 9\u2019s biology and clinical implications","volume":"27","author":"Seidah","year":"2016","journal-title":"Curr Opin Lipidol."},{"issue":"7446","key":"2022053123441944300_CIT0246","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature."},{"issue":"10","key":"2022053123441944300_CIT0247","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1172\/JCI137536","article-title":"Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes","volume":"130","author":"Gan","year":"2020","journal-title":"J Clin Invest."},{"issue":"3","key":"2022053123441944300_CIT0248","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell."},{"issue":"13","key":"2022053123441944300_CIT0249","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/1873-3468.13152","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibits interferon \u03b2 expression through interacting with ATF-2","volume":"592","author":"Li","year":"2018","journal-title":"FEBS Lett."},{"issue":"3","key":"2022053123441944300_CIT0250","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bcp.2014.11.013","article-title":"Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications","volume":"93","author":"Tikoo","year":"2015","journal-title":"Biochem Pharmacol."},{"issue":"5","key":"2022053123441944300_CIT0251","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00380-016-0936-5","article-title":"The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts","volume":"32","author":"Shin","year":"2017","journal-title":"Heart Vessels."},{"issue":"2","key":"2022053123441944300_CIT0252","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2020.06.015","article-title":"In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19","volume":"32","author":"Zhang","year":"2020","journal-title":"Cell Metab."},{"issue":"1","key":"2022053123441944300_CIT0253","doi-asserted-by":"crossref","first-page":"17458","DOI":"10.1038\/s41598-020-74492-0","article-title":"Statin use is associated with lower disease severity in COVID-19 infection","volume":"10","author":"Tan","year":"2020","journal-title":"Sci Rep."},{"key":"2022053123441944300_CIT0254","article-title":"Statins are associated with improved 28-day mortality in patients hospitalized with SARS-CoV-2 Infection","author":"Memel","year":"2021","journal-title":"medRxiv"},{"issue":"5","key":"2022053123441944300_CIT0255","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2020.06.006","article-title":"Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia","volume":"14","author":"Vuorio","year":"2020","journal-title":"J Clin Lipidol."},{"issue":"5","key":"2022053123441944300_CIT0256","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/joim.13210","article-title":"PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia","volume":"289","author":"Vuorio","year":"2021","journal-title":"J Intern Med."},{"key":"2022053123441944300_CIT0257","first-page":"eabd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume-title":"Science.","author":"Zhang","year":"2020"},{"issue":"1","key":"2022053123441944300_CIT0258","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2012.05.012","article-title":"Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity","volume":"12","author":"Gudleski-O\u2019Regan","year":"2012","journal-title":"Cell Host Microbe."},{"issue":"6","key":"2022053123441944300_CIT0259","doi-asserted-by":"crossref","first-page":"101043","DOI":"10.1016\/j.tranon.2021.101043","article-title":"Influence of cholesterol on cancer progression and therapy","volume":"14","author":"Mayengbam","year":"2021","journal-title":"Transl Oncol."},{"key":"2022053123441944300_CIT0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fphar.2013.00119","article-title":"The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics","volume":"4","author":"Cruz","year":"2013","journal-title":"Front Pharmacol."},{"issue":"1","key":"2022053123441944300_CIT0261","doi-asserted-by":"crossref","first-page":"e1033586","DOI":"10.1080\/23723556.2015.1033586","article-title":"LDL Receptor: An open route to feed pancreatic tumor cells","volume":"3","author":"Vasseur","year":"2016","journal-title":"Mol Cell Oncol."},{"issue":"8","key":"2022053123441944300_CIT0262","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1073\/pnas.1421601112","article-title":"Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma","volume":"112","author":"Guillaumond","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6257","key":"2022053123441944300_CIT0263","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature."},{"issue":"4916","key":"2022053123441944300_CIT0264","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.2569235","article-title":"Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans","volume":"245","author":"Schafer","year":"1989","journal-title":"Science."},{"issue":"1","key":"2022053123441944300_CIT0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jcb.21612","article-title":"A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744 832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy","volume":"104","author":"Wesierska-Gadek","year":"2008","journal-title":"J Cell Biochem."},{"issue":"7839","key":"2022053123441944300_CIT0266","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature."},{"issue":"1","key":"2022053123441944300_CIT0267","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41392-021-00530-6","article-title":"Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy","volume":"6","author":"Almeida","year":"2021","journal-title":"Signal Transduct Target Ther."},{"issue":"3","key":"2022053123441944300_CIT0268","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jacl.2017.04.001","article-title":"Can iPCSK9-induced hypocholesterolemia starve cancer cells?","volume":"11","author":"Gangloff","year":"2017","journal-title":"J Clin Lipidol."},{"issue":"12","key":"2022053123441944300_CIT0269","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia."},{"issue":"1","key":"2022053123441944300_CIT0270","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41467-018-06467-9","article-title":"A Mendelian randomization study of the effects of blood lipids on breast cancer risk","volume":"9","author":"Nowak","year":"2018","journal-title":"Nat Commun."},{"issue":"1","key":"2022053123441944300_CIT0271","doi-asserted-by":"crossref","first-page":"188581","DOI":"10.1016\/j.bbcan.2021.188581","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): a potential multifaceted player in cancer","volume":"1876","author":"Bhattacharya","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"4","key":"2022053123441944300_CIT0272","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein Cell."},{"issue":"11","key":"2022053123441944300_CIT0273","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.21873\/anticanres.11145","article-title":"Immune blockade inhibition in breast cancer","volume":"36","author":"Voutsadakis","year":"2016","journal-title":"Anticancer Res."},{"issue":"11","key":"2022053123441944300_CIT0274","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s12272-016-0850-5","article-title":"Immune checkpoint inhibitors for cancer treatment","volume":"39","author":"Park","year":"2016","journal-title":"Arch Pharm Res."},{"issue":"7","key":"2022053123441944300_CIT0275","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J Lipid Res."},{"issue":"40","key":"2022053123441944300_CIT0276","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1093\/eurheartj\/ehaa140","article-title":"The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development","volume":"41","author":"Demetz","year":"2020","journal-title":"Eur Heart J."},{"issue":"1","key":"2022053123441944300_CIT0277","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun."},{"issue":"2","key":"2022053123441944300_CIT0278","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.111.187419","article-title":"Proprotein convertase substilisin\/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates","volume":"340","author":"Liang","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"issue":"11","key":"2022053123441944300_CIT0279","doi-asserted-by":"crossref","first-page":"19180","DOI":"10.1002\/jcp.28612","article-title":"The immune functions of PCSK9: Local and systemic perspectives","volume":"234","author":"Liu","year":"2019","journal-title":"J Cell Physiol."},{"issue":"5","key":"2022053123441944300_CIT0280","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol."},{"issue":"7","key":"2022053123441944300_CIT0281","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1111\/cas.14934","article-title":"Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review","volume":"112","author":"Jin","year":"2021","journal-title":"Cancer Sci."},{"key":"2022053123441944300_CIT0282","doi-asserted-by":"crossref","DOI":"10.2174\/1381612827999210111182030","article-title":"The state of the problem of achieving extremely low LDL levels","author":"Korneva","year":"2021","journal-title":"Curr Pharm Des."},{"issue":"25","key":"2022053123441944300_CIT0283","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"2022053123441944300_CIT0284","first-page":"e201702","article-title":"The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol","volume":"2017","author":"Seidah","year":"2017","journal-title":"J Glob Cardiol Sci Pract."},{"issue":"3","key":"2022053123441944300_CIT0285","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/febs.15036","article-title":"Functional analysis of natural PCSK9 Mutants in modern and archaic humans","volume":"287","author":"Mikaeeli","year":"2020","journal-title":"FEBS J."},{"issue":"10","key":"2022053123441944300_CIT0286","doi-asserted-by":"crossref","first-page":"e1098","DOI":"10.1371\/journal.pone.0001098","article-title":"Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species","volume":"2","author":"Ding","year":"2007","journal-title":"PLoS One."},{"issue":"16","key":"2022053123441944300_CIT0287","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1111\/j.1742-4658.2008.06553.x","article-title":"Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion","volume":"275","author":"Cameron","year":"2008","journal-title":"FEBS J."},{"issue":"6820","key":"2022053123441944300_CIT0288","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/35054550","article-title":"Molecular phylogenetics and the origins of placental mammals","volume":"409","author":"Murphy","year":"2001","journal-title":"Nature."},{"issue":"1","key":"2022053123441944300_CIT0289","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10709-021-00113-x","article-title":"Patterns and tempo of PCSK9 pseudogenizations suggest an ancient divergence in mammalian cholesterol homeostasis mechanisms","volume":"149","author":"van Asch","year":"2021","journal-title":"Genetica."},{"issue":"10","key":"2022053123441944300_CIT0290","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4244\/EIJ-D-17-01028","article-title":"Plaque burden influences accurate classification of fibrous cap atheroma by in vivo optical coherence tomography in a porcine model of advanced coronary atherosclerosis","volume":"14","author":"Poulsen","year":"2018","journal-title":"Eurointervention."}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnab035\/41047068\/bnab035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/43\/3\/558\/43899684\/bnab035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/43\/3\/558\/43899684\/bnab035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T23:46:57Z","timestamp":1654040817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/43\/3\/558\/6385885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":290,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,10,9]]},"published-print":{"date-parts":[[2022,5,12]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnab035","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,9]]}}}